Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04173819 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 225
- Enrollment target
NCT04173819 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 225 participants.
The verdict
NCT04173819, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 225 participants
- Enrollment target
Study Summary
This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4 binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3 loop of HIV-1 envelope protein. The hypothesis is that the two antibodies will be safe for healthy HIV-1 uninfected adults when co-administered subcutaneously or intravenously and, after subcutaneous administration in the optimal ratio, each antibody will maintain serum levels \>10 µg/ml for at least 3 months in HIV-uninfected participants.
Interventions
- BIOLOGICAL 3BNC117-LS-J
- BIOLOGICAL 10-1074-LS-J
- BIOLOGICAL Combination 3BNC117-LS-J and 10-1074-LS-J
- BIOLOGICAL Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1
- BIOLOGICAL Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2019-01-25 |
| Est. Completion | 2023-09-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04173819
The ClinicalTrials.gov registry entry for NCT04173819 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which 3BNC117-LS-J is the first listed.
NCT04173819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04173819 about?
NCT04173819 is a clinical study titled "Safety and Pharmacokinetics of the Combination Broadly Neutralizing Antibodies, 3BNC117-LS-J and 10-1074-LS-J, in Healthy American and African Adults". This is a Phase 1/2 study to evaluate the safety, tolerability, and pharmacokinetics of two broadly neutralizing monoclonal human antibodies (bNAbs), 3BNC117-LS-J, which targets the CD4 binding site on HIV-1 envelope protein, and 10-1074-LS-J which targets the V3 loop of HIV-1 envelope protein. The ...
What is the current status of trial NCT04173819?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 225 participants. The study started on 2019-01-25. Estimated completion is 2023-09-01.
What interventions are being tested in trial NCT04173819?
The interventions under investigation include: 3BNC117-LS-J (BIOLOGICAL), 10-1074-LS-J (BIOLOGICAL), Combination 3BNC117-LS-J and 10-1074-LS-J (BIOLOGICAL), Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 1 (BIOLOGICAL), Combination 3BNC117-LS-J and 10-1074-LS-J Ratio 2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04173819?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.